Central Bank & Trust Co. Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Central Bank & Trust Co. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,042 shares of the biopharmaceutical company’s stock after selling 416 shares during the quarter. Central Bank & Trust Co.’s holdings in Gilead Sciences were worth $842,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Financial Counselors Inc. grew its holdings in Gilead Sciences by 11.6% during the first quarter. Financial Counselors Inc. now owns 9,892 shares of the biopharmaceutical company’s stock worth $725,000 after acquiring an additional 1,030 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $462,000. Larson Financial Group LLC lifted its holdings in shares of Gilead Sciences by 22.7% in the first quarter. Larson Financial Group LLC now owns 1,493 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 276 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $4,592,000. Finally, Catalina Capital Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $204,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $89.84 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $90.71. The stock has a market cap of $111.85 billion, a P/E ratio of 109.56, a PEG ratio of 3.12 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a 50-day moving average of $84.05 and a two-hundred day moving average of $74.38.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. On average, research analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last ninety days. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $78.00 to $100.00 in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $86.85.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.